Raegan Swaringen
Family · Salisbury, NCNPI 1013390574
Payments from drug & device makers
Across 318 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$879
- AstraZeneca$842
- Johnson & Johnson$834
- Takeda Pharmaceuticals U.S.A., Inc.$427
- Gilead$398
- Lilly USA, LLC$291
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,65698%
- Education$1602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $879 |
| AstraZeneca | 23 | $842 |
| Johnson & Johnson | 24 | $834 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $427 |
| Gilead | 20 | $398 |
| Lilly USA, LLC | 14 | $291 |
| Phathom Pharmaceuticals, Inc. | 12 | $262 |
| Aimmune Therapeutics, Inc. | 10 | $252 |
| Sanofi | 10 | $244 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $220 |
| Madrigal Pharmaceuticals | 9 | $203 |
| Regeneron Healthcare Solutions, Inc. | 7 | $185 |
| Amgen | 16 | $183 |
| GSK | 13 | $178 |
| Pfizer | 9 | $161 |
| United Therapeutics Corporation | 25 | $161 |
| Alnylam Pharmaceuticals Inc. | 7 | $153 |
| Grifols USA, LLC | 7 | $120 |
| Ardelyx, Inc. | 4 | $81 |
| Mylan Specialty L.p. | 4 | $74 |
| Merck | 4 | $71 |
| Baxter Healthcare | 4 | $67 |
| Novo Nordisk | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 3 | $48 |
| Celltrion USA Inc. | 2 | $45 |
| Electromed, Inc. | 3 | $43 |
| Boehringer Ingelheim | 2 | $42 |
| Ironwood Pharmaceuticals, Inc | 2 | $38 |
| Organon | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Philips North America LLC | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $20 |
| Smith+Nephew | 1 | $19 |
| Sandoz | 1 | $14 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| QOL Medical, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,817 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $92,380 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 105 | $84,121 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $35,005 |
| Spiriva RespimatTiotropium Bromide | 51 | $28,156 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $26,162 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $20,278 |
| SymbicortBudesonide/Formoterol Fumarate | 54 | $18,087 |
| LinzessLinaclotide | 28 | $16,795 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $12,307 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 144 | $9,303 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $9,013 |
| EliquisApixaban | 11 | $7,621 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 141 | $3,635 |
| Colestipol Hcl | 13 | $1,762 |
| Roflumilast | 12 | $1,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $178 | $153,547238 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $842 | $111,221170 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $42 | $60,741100 claims |
| AbbVieLinzess | $879 | $16,79528 claims |
| PfizerEliquis | $161 | $7,62111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Salisbury
- Karen GarmonSalisbury$15K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.